4-(2,5-Dichlorophenoxy)piperidine | 367501-13-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2,5-Dichlorophenoxy)piperidine
• CAS: 367501-13-1
• 化学式: C₁₁H₁₃Cl₂NO
• 分子量: 246.136
• InChiKey: NNKFUNWCEKSGND-UHFFFAOYSA-N

物化性质

• 沸点：
  339.8±42.0 °C(Predicted)
• 密度：
  1.256±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(2,5-Dichlorophenoxy)piperidine 、 2-[(3-Methoxycarbonylpyrazin-2-yl)amino]acetic acid 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 作用下， 生成
  参考文献：
  名称：

  Discovery of 1-(4-phenoxypiperidin-1-yl)-2-arylaminoethanone stearoyl-CoA desaturase 1 inhibitors

  摘要：

  A series of novel stearoyl-CoA desaturase 1 (SCD1) inhibitors were identified by scaffold design based on known SCD1 inhibitors. Large structural changes were made leading to multiple analogs with comparable or improved potency. This approach is valuable for generation of proprietary compounds without conducting a costly high-throughput screening. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.099

文献信息

• [EN] DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS<br/>[FR] DÉRIVÉS DE TRIAZINES ET D'URACILES, LEUR PRÉPARATION ET LEURS APPLICATIONS EN THÉRAPEUTIQUE HUMAINE
  申请人：PF MEDICAMENT

  公开号：WO2010006962A1

  公开（公告）日：2010-01-21

  The present invention relates to derivatives of general formula I wherein : - W represents nitrogen, - R1 represents: • a hydrogen or a linear or branched C1-C5 alkyl radical or, • a C1-C3 alkyl radical substituted with groups such as trifluoromethyl, nitrile, hydroxy, C1-C3 alcoxy, C3-C6 alkoxyalkoxy, indolyl, thiophenyl, oxothiophenyl, C1-C3 N-alkylcarbamoyl groups or, • a phenyl or pyridyl or naphthyl, or thiophenyl group optionally substituted with one or more groups such as halogen atoms, nitro, nitrile, trifluoromethyl, vinyl, methylsulfanyl, linear branched C1-C4 alkyl, linear or branched C1-C3 alkoxy groups, • a C6 2-oxocycloalkyl radical - R2 represents a methyl or heptyl, - m, n are equal to 1, - V represents CH2, - X-Y represents -N- (C=O) -, -CH-O-, - Z represents a phenyl group substituted with one or more trifluoromethyl groups, halogen atoms or linear C1-C4 alkyl groups.

  本发明涉及一般式I的衍生物，其中： - W代表氮， - R1代表： • 氢或直链或支链C1-C5烷基基团，或者 • 被三氟甲基、腈、羟基、C1-C3烷氧基、C3-C6烷氧基烷氧基、吲哚基、噻吩基、氧硫吩基、C1-C3 N-烷基氨基羰基基团取代的C1-C3烷基基团，或者 • 苯基或吡啶基或萘基，或者选择性地被一个或多个卤素原子、硝基、腈、三氟甲基、乙烯、甲硫基、直链或支链C1-C4烷基、直链或支链C1-C3烷氧基基团取代的噻吩基， • C6 2-氧代环烷基基团 - R2代表甲基或庚基， - m，n等于1， - V代表CH2， - X-Y代表-N- (C=O) -，-CH-O-，- Z代表被一个或多个三氟甲基基团、卤素原子或直链C1-C4烷基基团取代的苯基。
• Chemical compounds
  申请人：Rigby Aaron

  公开号：US20050171092A1

  公开（公告）日：2005-08-04

  The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.

  本发明提供了一个式子(I)的化合物：其中变量在此定义；以及制备这种化合物的过程；以及在治疗趋化因子（例如CCR3）或H1介导的疾病状态中使用这种化合物的用途。
• DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS
  申请人：Leroy Isabelle

  公开号：US20110118266A1

  公开（公告）日：2011-05-19

  The present invention relates to derivatives of general formula I wherein: —W represents nitrogen, —R 1 represents: •a hydrogen or a linear or branched C 1 -C 5 alkyl radical or, •a C 1 -C 3 alkyl radical substituted with groups such as trifluoromethyl, nitrile, hydroxy, C 1 -C 3 alcoxy, C 3 -C 6 alkoxyalkoxy, indolyl, thiophenyl, oxothiophenyl, C 1 -C 3 N-alkylcarbamoyl groups or, •a phenyl or pyridyl or naphthyl, or thiophenyl group optionally substituted with one or more groups such as halogen atoms, nitro, nitrile, trifluoromethyl, vinyl, methylsulfanyl, linear branched C 1 -C 4 alkyl, linear or branched C 1 -C 3 alkoxy groups, •a C 6 2-oxocycloalkyl radical—R 2 represents a methyl or heptyl, —m, n are equal to 1, —V represents CH 2 , —X—Y represents —N— (C═O)—, —CH—O—, —Z represents a phenyl group substituted with one or more trifluoromethyl groups, halogen atoms or linear C 1 -C 4 alkyl groups.

  本发明涉及一般式I的衍生物，其中：-W代表氮，-R1代表：•氢或线性或支链C1-C5烷基基团，或•C1-C3烷基基团，该基团被三氟甲基，腈，羟基，C1-C3烷氧基，C3-C6烷氧基烷氧基，吲哚基，噻吩基，氧代噻吩基，C1-C3N-烷基氨基甲酰基团取代，或•苯基或吡啶基或萘基，或噻吩基，可选地取代一个或多个卤原子，硝基，腈，三氟甲基，乙烯基，甲硫基，线性支链C1-C4烷基，线性或支链C1-C3烷氧基基团，•C62-氧代环烷基基团-R2代表甲基或庚基，-m，n等于1，-V代表CH2，-X-Y代表-N-(C═O)-，-CH-O-，-Z代表一个苯基，该苯基被一个或多个三氟甲基基团，卤原子或线性C1-C4烷基基团取代。
• Derivatives of triazines and uracils, their preparation and their application in human therapeutics
  申请人：Leroy Isabelle

  公开号：US08618287B2

  公开（公告）日：2013-12-31

  The present invention relates to derivatives of general formula I wherein: —W represents nitrogen, —R1 represents: •a hydrogen or a linear or branched C1-C5 alkyl radical or, •a C1-C3 alkyl radical substituted with groups such as trifluoromethyl, nitrile, hydroxy, C1-C3 alcoxy, C3-C6 alkoxyalkoxy, indolyl, thiophenyl, oxothiophenyl, C1-C3 N-alkylcarbamoyl groups or, •a phenyl or pyridyl or naphthyl, or thiophenyl group optionally substituted with one or more groups such as halogen atoms, nitro, nitrile, trifluoromethyl, vinyl, methylsulfanyl, linear branched C1-C4 alkyl, linear or branched C1-C3 alkoxy groups, •a C6 2-oxocycloalkyl radical—R2 represents a methyl or heptyl, -m, n are equal to 1, —V represents CH2, —X—Y represents —N— (C═O)—, —CH—O—, —Z represents a phenyl group substituted with one or more trifluoromethyl groups, halogen atoms or linear C1-C4 alkyl groups.

  本发明涉及一般式I的衍生物，其中：-W代表氮，-R1代表：•氢或线性或支链C1-C5烷基基团，或•C1-C3烷基基团，该基团被取代为三氟甲基、腈、羟基、C1-C3醇基、C3-C6烷氧基、吲哚基、噻吩基、氧代噻吩基、C1-C3 N-烷基氨基羰基基团或•苯基、吡啶基或萘基或噻吩基，或选配有一个或多个卤原子、硝基、腈、三氟甲基、乙烯基、甲基硫基、线性支链C1-C4烷基、线性或支链C1-C3烷氧基基团的基团，•C6 2-氧代环烷基基团-R2代表甲基或庚基，-m，n等于1，-V代表CH2，-X-Y代表—N—（C═O）—，—CH—O—，-Z代表苯基，该苯基被取代为一个或多个三氟甲基基团、卤原子或线性C1-C4烷基基团。
• Substituted bipiperidine intermediates and derivatives thereof
  申请人：AstraZeneca AB

  公开号：EP1493743A1

  公开（公告）日：2005-01-05

  A compound of formula (Xllla): wherein: L2 is hydrogen, tert-butoxycarbonyl or benzyl; t is 0 or 1; m and p are, independently, 0, 1 or 2; X is CH2, C(O), O, S, S(O), S(O)2 or NR37; provided that when m and p are both 1 then X is not CH2; and R1 has specified values.

  一种式(Xllla)化合物： 其中L2 是氢、叔丁氧基羰基或苄基；t 是 0 或 1；m 和 p 分别是 0、1 或 2；X 是 CH2、C(O)、O、S、S(O)、S(O)2 或 NR37；但当 m 和 p 均为 1 时，X 不是 CH2；R1 具有指定值。